Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reirradiation + Pembrolizumab in Recurrent SCCHN
NCT02289209Phase 2Completed
- Start
- Mar 2016
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in squamous cell carcinoma of the head and neck (HNSCC). Started Mar 2016; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02289209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289209.